Ronit Simantov

Ronit Simantov

Chief Tech/Sci/R&D Officer at GAMIDA CELL LTD.

Net worth: - $ as of 31/05/2026

61 year
Health Technology
Consumer Services

Profile

Ronit Simantov currently works at TempestTx, Inc., as Director and Gamida Cell Ltd., as Chief Medical & Scientific Officer.
Dr. Simantov also formerly worked at Bayer HealthCare Pharmaceuticals, Inc., as Oncology Director in 2007, Clovis Oncology, Inc., as Independent Director from 2021 to 2023, Tempest Therapeutics, Inc., as Independent Director from 2021 to 2026, Pfizer Inc., as Head-Oncology Global Medical Affairs from 2011 to 2017, CuraGen Corp., as Chief Medical Officer from 2007 to 2009, and OSI Pharmaceuticals, Inc., as Vice President-Clinical Research from 2010 to 2011.
Dr. Simantov received her undergraduate degree from The Johns Hopkins University and doctorate degree from New York University School of Medicine.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
27/01/2026 0 ( -.--% ) - $ 31/05/2026

Ronit Simantov active positions

CompaniesPositionStart
GAMIDA CELL LTD. Chief Tech/Sci/R&D Officer 01/07/2017
Director/Board Member -

Former positions of Ronit Simantov

CompaniesPositionEnd
TEMPEST THERAPEUTICS, INC. Director/Board Member 23/05/2026
CLOVIS ONCOLOGY, INC. Director/Board Member 10/07/2023
PFIZER INC. Corporate Officer/Principal 01/06/2017
OSI PHARMACEUTICALS, INC. Chief Tech/Sci/R&D Officer 01/06/2011
Chief Tech/Sci/R&D Officer 01/09/2009
See the detail of Ronit Simantov's experience

Training of Ronit Simantov

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

64

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

  1. Stock Market
  2. Insiders
  3. Ronit Simantov
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!